ArticleFrontiers in cardiovascular medicine2025
A study on the correlation between the mean platelet volume to monocyte count ratio and long-term prognosis in patients with newly diagnosed coronary artery disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary atherosclerotic heart disease (CAD) remains a major global health burden and a leading cause of mortality. Its pathogenesis is closely linked to multiple risk factors, among which inflammation plays a central role. While inflammatory biomarkers such as platelet and monocyte counts have been incorporated into prognostic assessments, their predictive accuracy remains limited. Further investigation of novel inflammatory indices is needed to refine risk stratification and guide clinical management. Objective: This study aimed to evaluate the prognostic value of the mean platelet volume-to-monocyte count ratio (MMR) for predicting major adverse cardiovascular events (MACE) in patients with newly diagnosed CAD. Methods: A total of 652 treatment-naïve CAD patients were enrolled. Kaplan-Meier survival analysis and univariate Cox proportional hazards models were applied to assess the association between MMR levels and MACE. Subgroup analyses were performed to test for effect modification. Restricted cubic spline (RCS) models were used to explore the dose-response relationship. The incremental predictive value of MMR beyond conventional risk factors was examined using changes in the concordance index (C-index), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: Patients were stratified into quintiles based on MMR values (L1: 7.89-14.43; L2: 14.50-17.96; L3: 18.00-22.16; L4: 22.25-28.53; L5: 28.67-60.67). Kaplan-Meier analysis revealed significantly poorer outcomes in the L3 group compared with other quintiles (log-rank Conclusion: In newly diagnosed CAD patients, MMR shows a nonlinear, inverted U-shaped association with MACE risk. The addition of MMR to standard risk models enhances prognostic accuracy. Further multicenter prospective studies and mechanistic trials are needed to verify the prognostic value of MMR and to elucidate its mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.